Known as the "Rambo Lambo," perfectly matched her larger-than-life persona. With custom touches that made it uniquely hers, ...
ORKA-002 has an NHP half-life of more than 30 days following subcutaneous and intravenous administration, over three times longer than bimekizumab. Projections of ORKA-002 pharmacokinetics (PK) in ...
Oragenics (OGEN) announced the submission of its Investigator’s Brochure application in preparation for its Phase II clinical trial using ...
This milestone represents an important step in advancing ONP-002, a novel intranasal neurosteroid, as a potential treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results